NR4A1 and invasive breast carcinoma: The version 3.2020 NCCN states that “the performance of axillary staging may be considered optional” for elderly patients or those with serious comorbidities (27), and the North American guidelines suggest that women >70 years old diagnosed with cN0 invasive breast cancer with positive hormone receptor should avoid routine use of SLNB (28).